[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"takayasus-arteritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:takayasus-arteritis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,77,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100228924","studies-of-the-natural-history-pathogenesis-and-outcome-of-idiopathic-systemic-vasculitis-100228924",false,"NCT02257866","Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis","* INCLUSION CRITERIA:\n\nSUBJECTS WITH VASCULITIS\n\n* Subjects who fulfill modified versions of the 1990 American College of Rheumatology (ACR) Classification Criteria for GPA31 and PAN\n* Subjects who fulfill the 1990 ACR Classification Criteria for EGPA, GCA, and TAK\n* Subjects who fulfill the 2012 Chapel Hill Nomenclature definition for MPA\n* Subjects with other suspected systemic or single-organ vasculitides\n\nHEALTHY VOLUNTEERS\n\n-Volunteers able to provide consent, or in the case of minors, assent\n\nEXCLUSION CRITERIA:\n\nSUBJECTS WITH VASCULITIS:\n\n* Subjects less than 3 years of age\n* Active malignancy, infection, or any medical condition that in the opinion of the investigator would warrant exclusion\n* Inability to provide consent, or in the case of minors, assent\n* Subjects with bleeding diathesis or on anticoagulant medications (e.g. coumadin, heparin, clopidogrel but not including aspirin or NSAIDs) are excluded from participation in nasal brushing or biopsy studies\n\nHEALTHY VOLUNTEERS\n\n* Volunteers less than 3 years of age\n* Diagnosis of vasculitis or other autoimmune\u002Fautoinflamamtory disease, including systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis, mixed connective tissue disease or any overlap autoimmune syndrome\n* Active malignancy, infection, or any medical condition that in the opinion of the investigator would warrant exclusion\n* Pregnant (by history of last menstrual period) or breast feeding subjects\n* Subjects with bleeding diathesis or taking anticoagulant medications (eg coumadin, heparin, clopidogrel but not including aspirin or NSAIDs) are excluded from participating in nasal brushing studies",true,"ALL","3 Years",{"count":19,"type":20},4000,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse. Researchers want to study people s genes and follow people over time to see how the disease affects them.\n\nObjective:\n\n\\- To learn the signs, symptoms, imaging tests, genetic markers, and blood tests that can help identify people with vasculitis and predict what will happen to them over time.\n\nEligibility:\n\n* People age 3 and older who have or are thought to have vasculitis, or are related to someone with it.\n* Healthy volunteers.\n\nDesign:\n\n* Participants will be evaluated by a doctor who has expertise caring for patients with vasculitis.\n* Participants will give a blood sample. Some will give a urine sample.\n* Some participants may have brushings or biopsies taken from the inside lining of the nose.\n* Images of participants blood vessels may be taken using scans. For some scans, participants will lie on a table that moves in and out of a cylinder that takes pictures. For some scans, a contrast agent may be injected into an arm vein. Other scans may use a radioactive form of sugar. Healthy minors will not have scans.\n* Some participants will answer questionnaires. - Some participants will have their tests done at NIH. Others will have their doctor take the blood, saliva, or cheek swab samples and send them to NIH.\n* Some participants will have one visit lasting 1-2 (but sometimes up to 4) days. Some participants may have follow-up visits every 3 - 6 months, indefinitely.",[24,25,26,27,28],"Takayasu's Arteritis","Giant Cell Arteritis","Polyarteritis Nodosa","Relapsing Polychondritis","ANCA-Associated Vasculitis",[26,30,31,27,32,33],"Takayasu's Arthritis","Giant Cell Arthritis","Antineutrophil Cytoplasmic Antibodies","Natural History","RECRUITING","2026-06-13",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":38},"2014-09-29",{"date":42,"type":20},"2050-01-01",{"name":44,"class":45},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100635876","global-initiative-on-takayasu-arteritis-gita-100635876","NCT07558382","Global Initiative on Takayasu Arteritis (GITA)","Takayasu's Arteritis Global Registry","GITA","Inclusion Criteria:\n\n* Each patient must fullfill the ACR 1990 or ACR\u002FEULAR 2021 criteria for Takayasu arteritis.\n* Patients (or legally acceptable representatives of subjects enrolled) have to\n* provide informed and free agreement to participate in the study and to disclose any medical event to the investigator. The parents or legally acceptable representative and the adolescent subject must be willing and able to comply with the study protocol requirements for the duration of the study\n* freely sign written and dated informed consent after being duly informed of the nature, significance, and implications of the study;\n* be informed that the patient enrolled may withdraw consent at any time without prejudice to future medical care.\n\nExclusion Criteria:\n\nPatients must be excluded from the study when the following criteria are observed:\n\n* The patient does not full-fill the ACR 1990 or ACR\u002FEULAR 2021 criteria for Takayasu arteritis\n* informed consent\u002Fassent is not provided and signed",{"count":56,"type":20},1000,"10 Years","Takayasu's Arteritis Global Registry aims to bring a large group of patients from different parts of the world to analyse and compare the patients' demographic, clinical, laboratory, radiological and prognostic features with outcomes, approaches to diagnosis, assessment, management and therapeutic interventions in different centers. The present project provides for both a retrospective and a prospective longitudinal study. The study is designed as retrospective for patients already diagnosed with TAK and treated with available treatments. Also, the study is designed as prospective for patients diagnosed with TAK after the initiation of the Registry or the adhesion to the project. This is thought as a multicentre, international study addressed to all Centers that will want to contribute to the present project. The study is non-interventional: demographic, clinical and therapeutic data required over time are collected with the routine diagnostic, clinical and therapeutic procedures usually carried out for the optimal management of patients and according with good clinical practice.",[60,24],"Takayasu Arteritis (TAK)",[62,63,64,65],"Takayasu's arteritis","prognosis","Registry","follow-up","2026-04-23",{"date":68,"type":38},"2026-04-30",{"date":70,"type":38},"2025-08-05",{"date":72,"type":20},"2035-08",{"name":74,"class":75},"Marmara University","OTHER",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100151303","one-time-dna-study-for-vasculitis-100151303","NCT01241305","One-Time DNA Study for Vasculitis","VCRC Genetic Repository One-Time DNA Protocol","Inclusion Criteria:\n\n1\\. Diagnostic criteria for Giant Cell Arteritis Age at disease onset \\>50 years (required)\n\n1. New onset or new type of localized pain in the head\n2. Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries)\n3. ESR of \\>40mm in the first hour by the Westergren method\n4. Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells)\n5. Large Vessel Vasculitis (LVV) by angiogram or biopsy not explained by something else\n\nInclusion Criteria:\n\n2\\. Diagnostic criteria for Takayasu's Arteritis\n\n1. Age at disease onset \\\u003C50 years\n2. Claudication of extremities\n3. Decreased brachial artery pulse (one or both arteries)\n4. Blood pressure difference of \\>10mm Hg between the arms\n5. Bruit over subclavian arteries or aorta\n6. Arteriogram abnormalities compatible with TAK (includes conventional dye angiography or MR angiography or CT angiography)\n\nInclusion Criteria:\n\n3\\. Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other causes) felt by investigator to be due to vasculitis\n\n1. Arteriographic abnormality\n2. Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy\n3. Mononeuropathy or polyneuropathy\n\nMinor criteria (not explained by other causes) felt by investigator to be due to vasculitis\n\n1. Weight loss \\> 4 kg\n2. Livedo reticularis, cutaneous ulcerations, or skin nodules\n3. Testicular pain or tenderness\n4. Myalgias\n5. Diastolic blood pressure \\> 90 mm Hg\n6. Elevated BUN or serum creatinine levels\n7. Ischemic abdominal pain\n\nIsolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN\n\nInclusion Criteria:\n\n4\\. Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangitis (MPA)\n\n* Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA \\& MPA.\n* For diagnosis of GPA meets at least 2 of the following 5 modified ACR criteria:\n\n  1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood\n  2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities\n  3. Urinary sediment with microhematuria or red cell casts\n  4. Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy\n  5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA\n* For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:\n\n  1. Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles)\n  2. Necrotizing arteritis involving small- and medium-sized arteries may be present\n  3. Necrotizing glomerulonephritis is very common\n  4. Pulmonary capillaritis often occurs\n\n     Inclusion Criteria:\n\n     5\\. Diagnostic criteria for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)\n     1. Asthma\n     2. Peak peripheral blood eosinophilia of \\>10% of total WBC\n     3. Peripheral neuropathy attributable to vasculitis\n     4. Transient pulmonary infiltrates on chest imaging studies\n     5. Paranasal sinus abnormalities or nasal polyposis\n     6. Eosinophilic inflammation on tissue biopsy\n\n     If patients have 4 of the above 6 criteria but lack clearcut documentation of small vessel vasculitis, they are also eligible for enrollment.\n\n     General Exclusion Criteria:\n* Inability to give informed consent and to sign the consent form\n* Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523\n* Unwilling to provide blood for DNA collection","7 Years",{"count":56,"type":20},"The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.",[88,25,89,90,26,24],"Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)","Granulomatosis With Polyangiitis (Wegener's)","Microscopic Polyangiitis",[92,93,94,95,96,97,98,99,100],"Vasculitis","CSS","EGPA","GCA","GPA","WG","MPA","PAN","TAK","2026-01-21",{"date":103,"type":38},"2026-01-22",{"date":105,"type":4},"2010-10",{"date":107,"type":20},"2028-08",{"name":109,"class":75},"University of Pennsylvania",14,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":15,"sex":16,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":46},"100314397","a-registry-study-on-biomarkers-of-takayasus-arteritis-arsbta-100314397","NCT03372980","A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)","A Registry Study on Biomarkers of Takayasu's Arteritis","Retrospective\n\nInclusion Criteria:\n\nSubjects who met the American College of Rheumatology 1990 classification criteria for Takayasu arteritis:\n\n1. Age of onset ≤40 years,\n2. Claudication of upper or lower extremities,\n3. Decreased pulsation of 1 or both brachial arteries,\n4. Difference of ≥ 10 mmHg in systolic blood pressure between arms,\n5. Bruit over subclavian arteries or aorta,\n6. \\*Arteriographic evidence showing a branch of the aorta stenosis or occlusion.\n\nMeeting more than 3 of 6 criteria suggests the diagnosis of Takayasu arteritis.\n\n\\*Angiography in this study was replaced by vascular magnetic resonance angiography(MRA)or computed tomography angiography(CTA).\n\nExclusion Criteria:\n\n1. Arteriographic lesions that could be entirely due to atherosclerosis,\n2. Suffer from other autoimmune diseases (eg, ANCA-associated vasculitis, systemic lupus erythematosus, etc.) besides Takayasu arteritis,\n3. Cogan's syndrome,\n4. Behcet's disease,\n5. Subjects with any serious acute or chronic infection,\n6. Giant cell arteritis (large vessel vasculitis and at least 50 years old) or other infectious forms of large vessel vasculitis.\n\nProspective\n\nInclusion Criteria:\n\nSubjects with initial suspicion of having Takayasu arteritis or patients with Takayasu arteritis need assessment of disease activity were prospectively enrolled.\n\nExclusion Criteria:\n\n1. Patients without image studies.\n2. Patients with confirmed other autoimmune diseases (eg, ANCA-associated vasculitis, systemic lupus erythematosus, etc.)","18 Years","70 Years",{"count":56,"type":20},"Takayasu arteritis is a chronic vasculitis mainly involving the aorta and its main branches such as the brachiocephalic, carotid, subclavian, vertebral, and renal arteries, as well as the coronary and pulmonary arteries. Inflammation causes segments of the vessels to become narrowed, blocked, or even stretched, possibly resulting in aneurysms. The disease is very rare but most commonly occurs in young Asian women. However, there is a considerable lack of understanding of the disease mechanism of Takayasu arteritis. Initially, the disease remains clinically silent (or remains undetected) until the patients present with vascular occlusion. Additionally, many individuals with Takayasu arteritis, however, have no apparent symptoms despite disease activity. Therefore, biomarkers for diagnosis and monitor disease activity in individuals with Takayasu arteritis are needed. In this study, the investigators therefore to use different methods to identify new biomarkers for diagnosing or monitoring the disease activity in individuals with Takayasu arteritis. These biomarkers may provide valuable insights into the underlying biochemical processes and aid the understanding of the pathophysiology of this disease.",[24],[124],"Biomarkers","2022-04-11",{"date":127,"type":38},"2022-04-12",{"date":129,"type":38},"2016-01",{"date":131,"type":20},"2026-12",{"name":133,"class":75},"Beijing Institute of Heart, Lung and Blood Vessel Diseases"]